Christian Kinch assumes role as senior advisor to Bactiguard and declines re-election to the board
The Nomination Committee of Bactiguard Holding AB (the "Company") today informs about the proposal regarding the composition of the Board of Directors for the Annual General Meeting on 14 May 2024.
The Nomination Committee proposes reelection of Thomas von Koch, Dr Richard Kuntz, Professor Anna Martling, Magdalena Persson and Jan Ståhlberg as Board Members. Christian Kinch has declined re-election. As the Company has appointed a new permanent CEO with effect from the Annual General Meeting at the latest, the Nomination Committee further proposes that Thomas von Koch is re-elected as the Company's Chairman of the Board of Directors.
All the proposed directors have agreed to serve on the Company’s Board of Directors. The Nomination Committee has not considered that Christian Kinch's decline for re-election requires any replacement. The composition and size of the Board is considered well suited to the phase that the Company is in.
"After 20 years in various roles within Bactiguard's corporate governance, as CEO, Board Member and Chairman, it is now time for me to contribute in a different way. I will continue to be deeply involved in Bactiguard's development and look forward to enter into a role as senior advisor to the Chairman of the Board and our new CEO. Our Board has been significantly strengthened in recent years and I feel more than confident in their ability to support and guide Bactiguard into the future as a global license-focused specialist organization. Declining re-election is a totally undramatic decision and I remain as one of Bactiguard's main owners. By stepping down from the Bactiguard board, I will balance my time with my other company holdings better and engage more in for instance SmartCella, which is in an exciting phase right now," says Christian Kinch, outgoing Board Member.
Thomas von Koch, Board Member and interim CEO comments: "Christian has served Bactiguard faithfully during all these years, both operationally and through the board. As we now enter the next phase of the Company's development, with Christine as the new CEO and me as the proposed Chairman, it will be very valuable to be able to discuss and get advice from Christian. I look forward to a continued close collaboration on Bactiguard where we will have access to both Christian's expertise in the MedTech industry and the historical perspective of Bactiguard. Simutaneously, I can focus on the overall strategic matters for Bactiguard and Christian can spend more time on SmartCella. I would like to take this opportunity to thank Christian for his passionate commitment, drive and always high energy when it comes to Bactiguard. This will an important part of our future success."
The Nomination Committee for the 2024 Annual General Meeting consists of Helena Borglund (Chairman of the Nomination Committee), appointed by TomBact AB (a company controlled by Thomas von Koch), Christian Kinch, appointed by GIDL Invest AB (a company controlled Christian Kinch), Mats J Andersson, appointed by Nordea Fonder AB, Jannis Kitsakis, appointed by the Fourth AP Fund, and Jan Ståhlberg, appointed by himself.
The Nomination Committee's motivation and complete proposals, as well as information about those proposed to the Board of Bactiguard Holding AB, will be included in the Notice to the Annual General Meeting 2024 which will be available on www.bactiguard.com
For further information, please contact:
Nina Nornholm, Head of Communication & Investor Relations +46 708 550 356
About Bactiguard
Bactiguard is a global MedTech company developing safe and biocompatible technology to prevent medical device related infections. The company’s unique technology is based on an ultra-thin noble metal coating that prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard’s infection prevention solutions decrease patient suffering, save lives, and unburden healthcare resources while also fighting against antimicrobial resistance, one of the most serious threats to global health and modern medicine. Bactiguard operates through license partnerships with leading global MedTech companies that apply the technology to their medical devices and sell them under their own brand or co-branded with Bactiguard. The company also has a portfolio of wound management products.
Bactiguard is headquartered in Stockholm and listed on Nasdaq Stockholm.
Read more about Bactiguard: www.bactiguard.com
Follow Bactiguard on LinkedIn